Roche Holding stock
Secondary listing. The primary listing is Roche Holding · SIX (CHF)
Price history
+38.07% over the period1 year: from CHF 300.00 (November 17, 2025) to CHF 414.20 (November 16, 2026), +38.07%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | CHF 414.20 |
| October 30, 2026 | CHF 411.20 |
| September 30, 2026 | CHF 360.80 |
| August 31, 2026 | CHF 360.40 |
| July 31, 2026 | CHF 358.60 |
| June 30, 2026 | CHF 339.20 |
| May 29, 2026 | CHF 336.60 |
| April 30, 2026 | CHF 326.60 |
| March 31, 2026 | CHF 327.20 |
| February 27, 2026 | CHF 381.40 |
| January 30, 2026 | CHF 356.00 |
| December 30, 2025 | CHF 335.20 |
| November 28, 2025 | CHF 319.40 |
| November 17, 2025 | CHF 300.00 |
At a glance
The company
Develop pharmaceuticals and diagnostics for diseases including cancer, infectious diseases, and respiratory disorders
Latest results
Quarter to September 30, 2026
Next event
TickerLandia's take on Roche Holding
- Pricier than usual relative to earnings: P/E on the latest fiscal year 26 vs a median of 21 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 27 vs 21 (+25%) in a group of 10.
- Strong point: Market momentum (78/100 in its group). Weak point: Growth (19/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−0.86% from the 52-week high
Analysts · 3 analysts
Average targetCHF 470.00+13.47% vs. price
Buy 1 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Roche Holding
Compared with similar companies: very low growth.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh69
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 26.4 59 Forward P/E 18.3 69 EV/EBITDA 14.6 70 Price/book 9.86 81 Price/sales 5.12 66 Profitabilityhigh71
How much it earns on revenue and capital.
Metric Value Position in group Net margin 19.6% 74 ROE 38.1% 77 ROA 13.5% 82 Operating margin 33.1% 62 Gross margin 74.2% 58 Earnings stabilityhigh70
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.3% 86 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthvery low19
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) −1.20% 2 Average revenue growth (3 years) −1.26% 14 Earnings growth (year over year) −7.70% 40 Financial strengthaverage43
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.12 50 Interest coverage 17.7 50 Current ratio 1.23 30 Debt/equitycounts in reverse: lower means more financial strength 0.91 44 Dividendhigh60
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 32 years 68 Payout ratio 63.9% 56 Dividend yield 2.4% 56 Market momentumstrong78
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +7.04% 72 Relative strength (6 months) +10.62% 76 1-year return +39.60% 82 Distance from 200-day average +16.80% 84 Riskaverage48
How much the price swings.
Metric Value Position in group Beta (1 year) 1.16 82 Volatility (60 days) 22.1% 29 Maximum drawdown (12 months) 19.5% 32
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Roche Holding is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Roche Holding's P/E today is 25.8, above the median of its last 10 fiscal years (21.1; between 18.3 and 26.2 from 2016 to 2025). Roche Holding's P/E (trailing 12 months): 26.9, +25% against the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | Roche Holding | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 26.9 | High | |
| Forward P/E | 18.7 | High | |
| Operating margin | 33.1% | Middle | |
| ROE | 38.1% | High | |
| Debt/equity | 0.91 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Roche Holding. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
CHF 31.45B
Latest quarter · Q2 2026
Net income
CHF 6.87B
Latest quarter · Q2 2026
Quarterly net margin
21.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 328.27B
- P/E
- 26.9
- EPS
- CHF 15.33
- Volume
- 19.04K
- Daily trading
- €12.12M
- Dividend yield
- 2.61%
- Last ex-dividend on March 12, 2026
How Roche Holding is changing
All resultsRevenue grew 1.0% a year on average over the last 5 years
Operating margin rose from 31.3% to 33.1%
Profits turn into cash: free cash flow equal to 121% of net income
Returns
Roche Holding returns with dividends
CHF 1,000 invested in Roche Holding 5 years ago, on November 16, 2021, would be worth CHF 1,220 today with dividends reinvested: +21.96% in total, +4.05% per year. On price alone it would be CHF 1,041 (+4.12%).
| Period | Roche Holding | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +7.70% | +8.46% | CHF 1,077 |
| 6 months | +24.83% | +14.27% | CHF 1,248 |
| Year to date | +23.57% | +13.86% | CHF 1,236 |
| 1 year | +42.62% | +19.91% | CHF 1,426 |
| 3 years | +82.06% | +41.93% | CHF 1,821 |
| 5 years | +21.96% | +20.30% | CHF 1,220 |
| 10 years | +141.76% | +90.88% | CHF 2,418 |
Over the last 6 months it has done better than 38% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Roche Holding: technical analysis
Roche Holding is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 4.3% below its all-time closing high (CHF 433.00, April 11, 2022).
- Trend
- Upward
- RSI (14 sessions)
- 67
- Between 30 and 70
- vs 200-session average
- +16.83%
Support and resistance
Price areas where Roche Holding has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 414.20
- SupportCHF 383.00−7.53%2 touches, last on August 26, 2026
- SupportCHF 378.50−8.62%4 touches, last on September 28, 2026
- SupportCHF 357.90−13.59%2 touches, last on August 14, 2026
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 1.20
- Volatility (60 sessions, annualised)
- 20.8%
- Largest fall in the last year
- −19.00%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Roche Holding: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Roche Holding has been July: +2.21% on average, positive in 22 years out of 37. The weakest has been February: −0.93% on average, positive in 18 years out of 37. November, the current month, has been positive in 21 years out of 36 (+1.62% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.32% | +1.28% | 23 of 36 |
| February | −0.93% | −0.83% | 18 of 37 |
| March | +0.15% | +1.22% | 20 of 37 |
| April | +1.66% | 0.00% | 18 of 37 |
| May | +1.94% | +2.05% | 23 of 37 |
| June | −0.25% | −0.96% | 15 of 37 |
| July | +2.21% | +1.02% | 22 of 37 |
| August | −0.64% | −0.45% | 14 of 37 |
| September | −0.81% | −0.65% | 16 of 37 |
| October | +1.56% | +2.11% | 24 of 37 |
| November | +1.62% | +0.91% | 21 of 36 |
| December | +0.84% | +0.25% | 18 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Roche Holding and its competitors
Based in Basel, Switzerland, Roche Holding AG was founded in 1896 and operates in pharmaceuticals and diagnostics. Its pharma portfolio covers therapeutic areas such as oncology, neurological disorders, ophthalmology, dermatology and transplantation. Its diagnostics business offers in vitro tests for diseases including cancer, diabetes and hepatitis, along with diagnostic instruments and digital health solutions. The group sells in Europe, North America, Latin America, Asia, Africa, Australia and New Zealand.
- Headquarters
- Basel, Switzerland
- Employees
- 103,249
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Roche HoldingRO | $391.54B | 33.1% | 26.9 | +24.83% |
| NovartisNOVN | $301.99B | 34.0% | 32.1 | +16.25% |
| AstraZenecaAZN | $286.82B | 25.8% | 26.5 | +2.92% |
| Novo NordiskNOVO.B | $181.48B | 50.8% | 10.9 | −3.84% |
| SanofiSAN | $116.24B | 22.3% | 25.3 | +18.71% |
| GSKGSK | $101.36B | 30.5% | 17.9 | +3.57% |
Same industry or related industries, similar size. Compare Roche Holding with its competitors · Full profile
